Breakthrough Research in Migraine Relief 01/20/11

In recent years medical research has shown that supplementation with the herb Butterbur can reduce the frequency of migraines by up to 77%.

These studies have been published in prestigious journals including, Neurology, Headache, Lancet, British Medical Journal, International Journal of Clinical and Pharmacological Therapies and others

The Gold Standard Dosage of Butterbur is 75 mg twice per day.

The herb should be standardized to contain 15% sesquiterpenes as petasines

These active constituents have been show to inhibit the onset of migraines in at least 3 important ways:

  1. Block production of inflammatory agents in the blood vessel wall
  2. Decrease blood vessel spasm
  3. Block histamine release

The herb Feverfew has also been show to reduce the frequency of migraine headaches.

If you are a migraine sufferer, then taking a supplement containing both Butterbur and Feverfew may be your best bet.

Other natural interventions that may also reduce migraine frequency, in addition to Butterbur and Feverfew supplementation, commonly include:

  • Monthly Chiropractic care
  • Regular Massage treatments
  • Relaxation techniques (Yoga, meditation, deep breathing etc)
  • Acupuncture

If you suffer migraines then check out my migraine supplement recommendations at meschinohealth.com at this link: http://www.meschinohealth.com/Conditions/Migraine_Headache/

Scientific References:

Butterbur

  1. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003; 60: 441–448.
  2. Silberstein SD, Lipton RB, Dalessio DJ, ed. Wolff’s headache and other head pain. 7th ed. Oxford, UK: Oxford University Press, 2001.
  3. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo controlled trial of feverfew in migraine prevention. Lancet. 1988; 2: 189–192.
  4. Johnson ES, Kadam NP, Hylands DM, Huylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985; 291: 569–573.
  5. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996; 16: 257–263.
  6. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998; 50: 466–470.
  7. Grossman M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther. 2000; 38: 430–435.
  8. Ziolo G, Samochewiec L. Study on clinical properties and mechanism of action of Petasites in bronchial asthma and chronic obstructive bronchitis. Pharm Acta Helv. 1998; 72: 359–380.
  9. Barsom S. Behandlung von Koliken und Spasmen in der Urologie mit einem pflanzlichen Spasmolytikum. Erfahrungsheilkunde. 1986; 35: 1–11.
  10. Gruia FS. Pflanzliche Analgetika–Therapie bei WS-Syndrom. Biol Med. 1987; 3: 454.
  11. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004; 51: 89–97.
  12. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8 (suppl 7): 1–96.
  13. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754–762.
  14. Gray RN, Goslin RE, McCrory DC, et al. Drug treatment for the prevention of migraine headache. Technical review 2.3, February 1999. Prepared for the Agency for Health Care Policy and Research under contract number 29009402025. Available from the National Technical Information Service; NTIS accession no. 127953.
  15. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995; 52: 281–286.
  16. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001; 41: 119–128.
  17. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001; 41: 968–975.
  18. Thomet OA, Wiesmann UN, Blaser K, Simon HU. Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophils. Clin Exp Allergy. 2001; 31: 1310–1320.
  19. Brune K, Bickel D, Peskar BA. Gastro-protective effects by extracts of Petasites hybridus: the role of inhibition of peptido-leukotriene synthesis. Planta Med. 1993; 59: 494–496.
  20. Scheidegger C, Dahinden C, Wiesmann U. Effects of extracts of individual components from Petasites on prostaglandin synthesis in cultured skin fibroblasts and on leucotriene synthesis in isolated human peripheral leucocytes. Pharm Acta Helv. 1998; 72: 359–380.
  21. Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon H. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol. 2001; 61: 1041–1047.
  22. Sheftell F, Rapoport A, Weeks R, Walker B, Gammerman I, Baskin S. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache. 2000; 40: 158–163.
  23. Pearlman EM, Fisher S. Preventive treatment for childhood and adolescent headache: role of once-daily montelukast sodium. Cephalalgia. 2001; 21: 461.
  24. Ko W, Lei C, Lin Y, Chen C. Mechanisms of relaxant action of S-petasine and S-Isopetasin, sesquiterpenes of Petasites formosanus, in isolated guinea pig trachea. Planta Med. 2001; 67: 224–229.
  25. Wang G-J, Shum AY-C, Lin Y-L, et al. Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasine, a hypotensive sesquiterpene from Petasites formosanus. J Pharmacol Exp Ther. 2001; 297: 240–246.
  26. Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache. 2003; 43: 76–78.
  27. Lipton RB, Göbel, H,Einhäupl KM,  Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neuorology. 2004 ; 63:2240-2244
  28. Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005;45:1-8.
  29. Mauskop A, Grossman WM, Schmidramsl H. Petasites hybridus (Butterbur root) extract is effective in the prophylaxis of migraines: results of a randomized, double blind trial. Headache. 2000;40:420.

Feverfew

  1. Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew and vascular smooth muscle: extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med. 1993;59(1):20-25.
  2. Chen CF, Leung AY. Gene response of human monocytic cells for the detection of antimigraine activity of feverfew extracts. Can J Physiol Pharmacol. 2007;85(11):1108-15.
  3. Curry EA 3rd, Murry DJ, Yoder C, et al., Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs. 2004;22(3):299-305.
  4. De Weerdt CJ, Bootsma HPR, Hendriks H. Herbal Medicines in migraine prevention. Randomized double-blind placebo controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3:225–230.
  5. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention–a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. 2005;25(11):1031-41.
  6. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr. 2000;3(4A):509-514.
  7. Evans RW, Taylor FR. “Natural” or alternative medications for migraine prevention. Headache. 2006;46(6):1012-8.
  8. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57(13):1221-1227.
  9. Henneicke-von Zepelin HH. Feverfew for migraine prophylaxis. Headache. 2006;46(3):531
  10. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985;291:569–573.
  11. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm. 1999;56(2):125-138; quiz 139-141.
  12. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004;44(9):885-90.
  13. Martin K, et al. Parthenolide-depleted Feverfew (Tanacetum parthenium) protects skin from UV irradiation and external aggression. Arch Dermatol Res. 2008;300(2):69-80.
  14. Mauskop A. Alternative therapies in headache. Is there a role? [Review] Med Clin North Am. 2001;85(4):1077-1084.
  15. Miller L. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158(20):2200–2211.
  16. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–192.
  17. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind controlled study. Phytotherapy Res. 1997;11:508–511.
  18. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double-blind, placebo controlled study. Ann Rheum Dis. 1989;48:547–549.
  19. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis–a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22(7):523-532.
  20. Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. [Review] Cochrane Database Syst Rev. 2000;(3).
  21. Shrivastava R, Pechadre JC, John GW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig. 2006;26(5):287-96.
  22. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol. 2005;18(3):289-92.
  23. Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol. 1992;43(11):2313-2320.
  24. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia. 1998;18(10):704-708.
  25. Won YK, Ong CN, Shi X, Shen HM. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis. 2004;25(8):1449-58.
  26. Wu C, Chen F, Rushing JW, Wang X, Kim HJ, Huang G, Haley-Zitlin V, He G. Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. J Med Food. 2006;9(1):55-61.
  27. Yao M, Ritchie HE, Brown-Woodman. A reproductive screening test of feverfew: is a full reproductive study warranted? Reprod Toxicol. 2006;22(4):688-93.
  28. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM. Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis. 2004;25(11):2191-9.
Be Sociable, Share!

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

You must be logged in to post a comment.